Previous Article | Next Article ![]()
Infect. Immun., 04 1997, 1204-1210, Vol 65, No. 4
DA Brake, CH Fedor, BW Werner, TJ Miller, RL Taylor Jr and RA Clare
A model to simulate natural immunity to Eimeria tenella was developed in
three chicken lines which differ at the B locus of the major
histocompatibility complex. Homozygous, 1-day-old chicks of the B19B19,
B24B24, or B30B30 genotype were trickle immunized by being orally fed a
small infectious dose of E. tenella oocysts for 5 consecutive days. These
naturally exposed birds were then challenged at different times between 5
and 24 days after the final dose, and the level of protection was assessed
6 days after challenge, using body weight gain and intestinal lesion
scores. The duration of immunity in naturally exposed birds differed among
the major histocompatibility complex lines. Trickle immunization of the
B19B19 haplotype afforded the longest and strongest level of protection
compared to the other two haplotypes tested. In addition, in vitro splenic
and peripheral blood lymphocyte proliferative responses in
trickle-immunized birds were measured against sporozoite, merozoite, and
tissue culture-derived E. tenella parasite antigens isolated from the
recently described SB-CEV-1/F7 established cell line. The lymphocytes
obtained from B19B19 birds trickle immunized responded in vitro to the E.
tenella-infected SB-CEV- 1/F7 tissue culture-derived parasite antigen.
Furthermore, antigen- specific immune responses appeared earlier in immune,
challenged B19B19 birds than in their naive, challenged counterparts. The
development of a model simulating natural immunization will serve as a
foundation to further characterize both humoral and cell-mediated responses
to E. tenella tissue culture-derived parasite antigens and to better
understand host protective immune responses to avian coccidiosis.
Copyright © 1997, American Society for Microbiology
Characterization of immune response to Eimeria tenella antigens in a natural immunity model with hosts which differ serologically at the B locus of the major histocompatibility complex
Animal Health Biological Discovery, Pfizer Central Research Division, Pfizer, Inc., Groton, Connecticut 06340, USA. david_brake@groton.pfizer.com
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|